Chamow & Associates is pleased to present a blog series detailing best practices for working with a contract development and manufacturing organization (CDMO). This series is intended to provide a…
Once again, the journal mAbs has published its 11th annual “Antibodies to Watch” article as an overview of exciting antibody products staged for significant advances in the coming year, authored…
Chamow & Associates is pleased to present a blog series detailing best practices for working with a contract development and manufacturing organization (CDMO). This series is intended to provide a…
South San Francisco is home to the largest biotech cluster in the world, with over 200 biotech companies, and 11.5-million square feet of biotech space on 500 acres. But 16…
Chamow & Associates is pleased to present a blog series detailing best practices for working with a contract development and manufacturing organization (CDMO). This series is intended to provide a potential…
Monoclonal antibodies (mAbs) as a therapeutic modality were developed over an 11-year period, from the first production of mAbs in 1975 to the first licensing of mAb therapeutic Orthoclone OKT3…
After the 2014 Ebola outbreak in West Africa, researchers wanted to test ZMapp, a new, experimental drug that had been used during that outbreak on some infected patients, along with…
The approval of Zolgensma (onasemnogene abeparvovexioi) in May of this year was quite a milestone for the Cell and Gene Therapy world. Zolgensma is an Adenovirus Associated Virus (AAV)-based gene…
One of the most challenging aspects in developing new mAb therapeutics is target discovery. Identification of new, validated and preferably functional targets is difficult to sustain and is clearly a…
Because recombinant protein therapeutics are genetically engineered, they have the potential to induce an immunogenic response in a patient. Immunogenicity risk, as defined by the formation of anti-drug antibodies (ADA),…